Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230004 | 0.92 | HIF1A (0.56) | HIF1ATHRATHRB | |
| SCHEMBL2761876 | 0.88 | KDM4E (0.53) | HIF1A | |
| SCHEMBL2762048 | 0.88 | MAOB (0.46) | — | |
| SCHEMBL2761593 | 0.86 | HIF1A (0.61) | HIF1ATHRATHRB | |
| SCHEMBL2761875 | 0.83 | ALDH1A1 (0.46) | — | |
| SCHEMBL934454 | 0.82 | — | — | |
| SCHEMBL2761573 | 0.82 | EGLN1 (0.48) | — | |
| SCHEMBL2761657 | 0.81 | EGLN1 (0.43) | — | |
| SCHEMBL2761688 | 0.81 | L3MBTL1 (0.52) | HIF1A | |
| SCHEMBL2761870 | 0.80 | EGLN3 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885THRA 1962/4885THRB 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.